pipeline
ANG-3777
Mechanism of Action
ANG-3777 is an HGF mimetic engineered to bind to the c-Met receptor and activate the pathways involved in tissue repair and complement the endogenous mismatch between HGF levels and c-Met expression after organ injury.
Clinical Trials
Acute Kidney Injury after Renal Transplantation: ANG-3777 is currently in a randomized, double-blind placebo-controlled Phase 3 trial for the treatment of acute kidney injury associated with delayed graft function. Data are expected in 2020.
Acute Kidney Injury after Cardiac Surgery: A randomized, double-blind, placebo-controlled Phase 2 trial examining the efficacy of ANG-3777 in reducing acute kidney injury in 240 patients after a cardiac procedure is currently enrolling. Data are expected in 2020.
ANG-3070
Mechanism of Action
ANG-3070 is an orally-bioavailable small molecule exhibiting preferential activity against fibrokinases – molecular pathways associated with poor outcomes in fibrotic conditions.
Clinical Trials
Healthy Volunteer Study: ANG-3070 is currently in a Phase 1 healthy volunteer trial. Data are expected in 2020.
Preclinical Studies
• Pulmonary Fibrosis
• Acute Colitis
• Renal Disease and Fibrosis
ROCK2 INHIBITOR
Mechanism of Action
An orally bioavailable small molecule ROCK2 inhibitor binding to serine/threonine kinase, which regulates cytokinesis, smooth muscle contraction, the formation of actin stress fibers, and focal adhesions.
Preclinical Studies
• Chronic Kidney Disease
• Biliary Sclerosis
• Nonalcoholic Steatohepatitis (NASH)
